SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
|
Schedule of financial assets and liabilities measured at fair value on recurring basis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements |
|
|
as of December 31, 2021 Using: |
|
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability |
|
$ |
— |
|
$ |
18,223 |
|
$ |
— |
|
$ |
18,223 |
Contingent consideration |
|
|
— |
|
|
— |
|
|
12,179,476 |
|
|
12,179,476 |
Derivative liability |
|
|
— |
|
|
— |
|
|
2,294,720 |
|
|
2,294,720 |
|
|
$ |
— |
|
$ |
18,223 |
|
$ |
14,474,196 |
|
$ |
14,492,419 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements |
|
|
as of December 31, 2020 Using: |
|
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability |
|
$ |
— |
|
$ |
— |
|
$ |
6,265 |
|
$ |
6,265 |
|
|
$ |
— |
|
$ |
— |
|
$ |
6,265 |
|
$ |
6,265 |
|
Schedule of changes in common stock warrant liability |
|
|
|
|
|
|
Warrant |
|
|
Liability |
Outstanding as of December 31, 2020 |
|
$ |
6,265 |
Change in fair value |
|
|
11,958 |
Outstanding as of December 31, 2021 |
|
$ |
18,223 |
|
Schedule of changes in contingent consideration |
|
|
|
|
|
|
Contingent |
|
|
Consideration |
|
|
Liability |
Balance as of December 31, 2020 |
|
$ |
— |
Initial recognition in connection with acquisition of Harper & Jones |
|
|
3,421,516 |
Stock price guarantee per consulting agreement |
|
|
67,000 |
Conversion into shares |
|
|
(73,500) |
Change in fair value |
|
|
8,764,460 |
Outstanding as of December 31, 2021 |
|
$ |
12,179,476 |
|
Summary of changed in derivative liability |
|
|
|
|
|
|
Derivative |
|
|
Liability |
Outstanding as of December 31, 2020 |
|
$ |
— |
Initial fair value on issuance of convertible note |
|
|
3,204,924 |
Change in fair value |
|
|
(910,204) |
Outstanding as of December 31, 2021 |
|
$ |
2,294,720 |
|
Schedule of estimated useful lives of amortizable intangible assets |
|
|
|
Customer relationships |
|
3 years |
|
Schedule of potentially dilutive items outstanding |
|
|
|
|
|
|
|
December 31, |
|
|
2021 |
|
2020 |
Convertible notes |
|
4,791,192 |
|
— |
Series Seed Preferred Stock (convertible to common stock) |
|
— |
|
20,714,518 |
Series A Preferred Stock (convertible to common stock) |
|
— |
|
5,654,072 |
Series A-2 Preferred Stock (convertible to common stock) |
|
— |
|
5,932,742 |
Series CF Preferred Stock (convertible to common stock) |
|
— |
|
836,331 |
Series A-3 Preferred Stock (convertible to common stock) |
|
— |
|
9,032,330 |
Series B Preferred Stock (convertible to common stock) |
|
— |
|
20,754,717 |
Common stock warrants |
|
3,580,116 |
|
914,539 |
Preferred stock warrants |
|
— |
|
806,903 |
Stock options |
|
3,895,103 |
|
1,163,103 |
Total potentially dilutive shares |
|
12,266,411 |
|
65,809,254 |
|